Phase II Trial of Amrubicin for Second-Line Treatment of Advanced Non-small Cell Lung Cancer: Results of the West Japan Thoracic Oncology Group Trial (WJTOG0401)
Open Access
- 1 January 2010
- journal article
- research article
- Published by Elsevier in Journal of Thoracic Oncology
- Vol. 5 (1) , 105-109
Abstract
No abstract availableKeywords
This publication has 21 references indexed in Scilit:
- Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trialThe Lancet, 2008
- Amrubicin for non-small-cell lung cancer and small-cell lung cancerInvestigational New Drugs, 2007
- Phase II study of amrubicin, 9-amino-anthracycline, in patients with advanced non-small-cell lung cancer: a West Japan Thoracic Oncology Group (WJTOG) studyInvestigational New Drugs, 2007
- Cancer Statistics, 2007CA: A Cancer Journal for Clinicians, 2007
- Phase II study of amrubicin in previously untreated patients with extensive-disease small cell lung cancer: West Japan Thoracic Oncology Group (WJTOG) studyInvestigational New Drugs, 2006
- Multicenter phase II study of amrubicin, 9-amino-anthracycline, in patients with advanced non-small-cell lung cancer (Study 1): West Japan Thoracic Oncology Group (WJTOG) trialInvestigational New Drugs, 2006
- Erlotinib in Previously Treated Non–Small-Cell Lung CancerNew England Journal of Medicine, 2005
- New Guidelines to Evaluate the Response to Treatment in Solid TumorsJNCI: Journal of the National Cancer Institute, 2000
- Tumor-selective Distribution of an Active Metabolite of the 9-Aminoanthracycline AmrubicinJapanese Journal of Cancer Research, 1998
- Optimal two-stage designs for phase II clinical trialsControlled Clinical Trials, 1989